A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
NNC0519-0130 is a new medicine to improve the treatment options for people living with type 2 diabetes and people with overweight. In this study one dose of NNC0519-0130 will be given and blood levels of NNC0519-0130 will be compared between people with reduced kidney function and people with normal kidney function. The study will last up to 52 days including a screening phase of up to 28 days prior to dosing.
Epistemonikos ID: 61d376ec76d83c60bfb6118a5d1870dec72992f3
First added on: May 15, 2024